A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.
ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.
Despite lower prevalence rates, women with steatotic liver disease related to alcohol consumption had close to double the risk of dying than men with the same condition.
A retrospective analysis revealed a strong positive link between higher HDL-C levels and the reversal of prediabetes to normoglycemia in Chinese adults up to a certain threshold.